NASDAQ$INSM
Insmed Incorporated · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Insmed's Q3 2024 earnings were reported, featuring revenue growth and progress in clinical and regulatory milestones.
Insmed reported Q3 2024 financial results, with total revenue reaching $93.4 million, an 18% increase year-over-year. The company is on track to file an NDA for brensocatib in Q4 2024 and anticipates a potential U.S. launch in mid-2025. Insmed ended the quarter with approximately $1.5 billion in cash, cash equivalents, and marketable securities.
- Total revenue for Q3 2024 was $93.4 million, reflecting an 18% increase year-over-year.
- ARIKAYCE global revenue grew by 18% compared to Q3 2023, with double-digit growth in the U.S., Japan, and Europe.
- The NDA submission for brensocatib in bronchiectasis is on track for Q4 2024, with a potential U.S. launch expected in mid-2025.
- Insmed ended the third quarter with approximately $1.5 billion in cash, cash equivalents, and marketable securities.
Headline financials
Revenue & EPS history
Insmed · Revenue · Quarterly
$93.4M
Revenue by segment
Insmed · $73.3M total across 2 segments · Q2 2023
- ARIKAYCE U.S.$57.7M—78.7%
- ARIKAYCE International$15.6M—21.3%
Forward guidance
Insmed reiterates its full-year 2024 global ARIKAYCE revenues guidance in the range of $340 million to $360 million, representing 15% year-over-year growth at the midpoint compared to 2023.
Tailwinds
- Commercialization and continued growth of ARIKAYCE in its current indication globally.
- Advancement of the clinical trial program intended to potentially support label expansion to include all patients with a MAC lung infection.
- Satisfaction of the post-marketing requirement for full approval of ARIKAYCE's current indication.
- Advancement of brensocatib, including activities related to regulatory filing and commercial launch readiness for bronchiectasis.
- Ongoing Phase 2 BiRCh trial in patients with CRSsNP and the anticipated Phase 2 program in HS.
Headwinds
- Failure to continue to successfully commercialize ARIKAYCE.
- Inability to obtain full approval of ARIKAYCE from the FDA.
- Failure to obtain regulatory approvals for brensocatib, TPIP, or other product candidates.
- Uncertainties in market acceptance of ARIKAYCE or brensocatib or TPIP.
- Inability to obtain and maintain adequate reimbursement from government or third-party payors.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-1.2%
Avg return
Earnings day
-0.2%
Avg return
5 days after
+1.8%
Avg return
30 days after
35%
23 / 65 earnings
Positive
+27.5%
Q2 2022
Best reaction
-23.3%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -23.3% | -15.4% | -31.3% | |
| Q4 2025 | +6.3% | +5.0% | -10.0% | |
| Q3 2025 | +16.3% | +9.5% | +24.5% | |
| Q1 2025 | -4.0% | -3.8% | +7.8% | |
| Q4 2024 | -0.3% | -7.6% | -4.7% | |
| Q3 2024 | -2.8% | -1.4% | +6.9% | |
| Q2 2024 | +4.2% | +7.6% | +0.1% | |
| Q1 2024 | -0.1% | -2.1% | +118.7% | |
| Q4 2023 | -3.4% | +3.5% | -6.4% | |
| Q3 2023 | -6.2% | -1.5% | -5.6% | |
| Q2 2023 | +1.0% | +1.3% | +4.0% | |
| Q1 2023 | -2.0% | -4.4% | -1.3% | |
| Q4 2022 | -3.9% | -2.4% | -21.2% | |
| Q3 2022 | -1.1% | -1.2% | +4.0% | |
| Q2 2022 | +27.5% | +26.6% | +12.8% | |
| Q1 2022 | -9.9% | -19.6% | -14.5% | |
| Q4 2021 | -5.2% | -6.5% | +0.9% | |
| Q3 2021 | +14.2% | +21.3% | +9.6% | |
| Q2 2021 | +3.4% | -2.3% | +15.1% | |
| Q1 2021 | +6.7% | -11.7% | -17.0% | |
| Q4 2020 | -10.6% | -3.9% | -13.4% | |
| Q3 2020 | -6.4% | -6.8% | +13.1% | |
| Q2 2020 | +14.8% | +7.9% | +2.5% | |
| Q1 2020 | +6.5% | +13.4% | +15.4% | |
| Q4 2019 | -11.8% | -16.6% | -38.0% | |
| Q3 2019 | +10.4% | +16.6% | +36.9% | |
| Q2 2019 | -20.7% | -22.5% | -25.1% | |
| Q1 2019 | -11.7% | -11.5% | -27.8% | |
| Q4 2018 | +14.3% | +17.0% | +10.3% | |
| Q3 2018 | -4.2% | +7.2% | +15.0% | |
| Q2 2018 | +5.6% | -1.6% | -19.5% | |
| Q1 2018 | +3.9% | +2.0% | +13.9% | |
| Q4 2017 | +8.1% | -0.8% | -11.1% | |
| Q3 2017 | +10.3% | +10.8% | +13.9% | |
| Q2 2017 | -8.6% | -17.2% | -20.7% | |
| Q1 2017 | -3.2% | -7.4% | -15.6% | |
| Q4 2016 | -1.1% | +9.5% | +8.7% | |
| Q3 2016 | -6.7% | +0.8% | +4.7% | |
| Q2 2016 | -0.2% | +0.3% | +13.4% | |
| Q1 2016 | +0.4% | — | — | |
| Q4 2015 | -2.3% | — | — | |
| Q3 2015 | -20.0% | — | — | |
| Q2 2015 | -2.4% | — | — | |
| Q1 2015 | +5.6% | — | — | |
| Q4 2014 | +3.4% | — | — | |
| Q3 2014 | -0.4% | — | — | |
| Q2 2014 | -9.3% | — | — | |
| Q1 2014 | +5.2% | — | — | |
| Q4 2013 | -7.8% | — | — | |
| Q3 2013 | -1.8% | — | — | |
| Q2 2013 | -2.8% | — | — | |
| Q1 2013 | -5.0% | — | — | |
| Q4 2012 | +5.5% | — | — | |
| Q3 2012 | +4.8% | — | — | |
| Q2 2012 | -6.8% | — | — | |
| Q1 2012 | -19.5% | — | — | |
| Q4 2009 | -0.3% | — | — | |
| Q4 2011 | -0.3% | — | — | |
| Q3 2011 | -3.7% | — | — | |
| Q2 2011 | -4.7% | — | — | |
| Q4 2010 | -4.7% | — | — | |
| Q1 2011 | -6.4% | — | — | |
| Q3 2010 | +4.1% | — | — | |
| Q2 2010 | -1.9% | — | — | |
| Q1 2010 | -12.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro